ПРЕЖДЕВРЕМЕННАЯ НЕДОСТАТОЧНОСТЬ ЯИЧНИКОВ, СОВРЕМЕННЫЙ ВЗГЛЯД НА ПРОБЛЕМУ


Кравченко Е.Н., Воронцова М.С.

Аннотация


Преждевременная недостаточность яичников (ПНЯ) – актуальная проблема, приводящая к стойкому нарушению качества жизни, преждевременному развитию остеопороза, сердечно-сосудистых заболеваний и стойкому нарушению репродуктивной функции (бесплодию). Ввиду полиэтиологичности, на сегодняшний день не существует универсального метода профилактики, а существующие методы лечения могут только скомпенсировать клинические симптомы, но не могут вернуть репродуктивную функцию. Своевременное выявление пациенток групп риска, совместное их ведение с узкими специалистами (репродуктолог, терапевт, эндокринолог), может существенно улучшить продолжительность и качество жизни этих женщин.


Ключевые слова


преждевременная недостаточность яичников; бесплодие; аменорея; остеопороз

Полный текст:

Full Text HTML Full Text PDF

Литература


Panay N, Anderson RA, Nappi RE, Vincent AJ, Vujovic S, Webber L, Wolfman W. Premature ovarian insufficiency: an International Menopause Society White Paper. Climacteric. 2020; 23(5): 426-446. doi: 10.1080/13697137.2020.1804547

Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016; 106(7): 1588-1599. doi: 10.1016/j.fertnstert.2016.09.046

Tsiligiannis S, Panay N, Stevenson JC. Premature Ovarian Insufficiency and Long-Term Health Consequences. Curr Vasc Pharmacol. 2019; 17(6): 604-609. doi: 10.2174/1570161117666190122101611

Ford EA, Beckett EL, Roman SD, McLaughlin EA, Sutherland JM. Advances in human primordial follicle activation and premature ovarian insufficiency. Reproduction. 2020; 159(1): R15-R29. doi: 10.1530/REP-19-0201

Rudnicka E, Kruszewska J, Klicka K, Kowalczyk J, Grymowicz M, Skórska J, Pięta W, Smolarczyk R. Premature ovarian insufficiency – aetiopathology, epidemiology, and diagnostic evaluation. Prz Menopauzalny. 2018; 17(3): 105-108. doi: 10.5114/pm.2018.78550

Barros F, Carvalho F, Barros A, Dória S. Premature ovarian insufficiency: clinical orientations for genetic testing and genetic counseling. Porto Biomed J. 2020; 5(3): e62. doi: 10.1097/j.pbj.0000000000000062

Jiao X, Ke H, Qin Y, Chen ZJ. Molecular Genetics of Premature Ovarian Insufficiency. Trends Endocrinol Metab. 2018; 29(11): 795-807. doi: 10.1016/j.tem.2018.07.002

Kirshenbaum M, Orvieto R. Premature ovarian insufficiency (POI) and autoimmunity-an update appraisal. J Assist Reprod Genet. 2019; 36(11): 2207-2215. doi: 10.1007/s10815-019-01572-0

Webber L, Anderson RA, Davies M, Janse F, Vermeulen N. HRT for women with premature ovarian insufficiency: a comprehensive review. Hum Reprod Open. 2017; 2017(2): hox007. doi: 10.1093/hropen/hox007

European IVF-monitoring Consortium (EIM), European Society of Human Reproduction and Embryology (ESHRE), Calhaz-Jorge C, De Geyter C, Kupka MS, de Mouzon J, et al. Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE. Hum Reprod. 2017; 32(10): 1957-1973

Ortmann O, Beckermann M, Inwald E, Strowitzki T, Windler E, Tempfer C. Peri- and postmenopause – diagnosis and interventions interdisciplinary S3 guideline of the association of the scientific medical societies in Germany (AWMF 015/062): short 41 version. Arch Gynecol Obstet. 2020; 302. doi: 10.1007/s00404-020-05682-4

Armeni E. et al. Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016; 89: 63-72. doi: 10.1016/j.maturitas.2016.04.013

Lumsden MA. The NICE Guideline – Menopause: diagnosis and management. Climacteric. 2016; 19(5): 426-429. doi: 10.1080/13697137.2016.1222483

Stuenkel CA, et al. Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100(11): 3975-4011. doi: 10.1210/jc.2015-2236

National Collaborating Centre for Women’s and Children’s Health (UK). Menopause: Full Guideline. London: National Institute for Health and Care Excellence. London, 2015

Munro MG, Critchley HOD, Fraser IS, FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet. 2018; 143(3): 393-408. doi: 10.1002/ijgo.12666

Menopause Practice (5th Edition): A Clinician’s Guide. The North American Menopause Society, 2014

O’Flynn N. Assessment and treatment for people with fertility problems: NICE guideline. Br J Gen Pract. 2014; 64(618): 50-51

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018; 33(9): 1602-1618

Gordon CM, Ackerman KE, Berga SL, Kaplan JR, Mastorakos G, Misra M, et al. Functional Hypothalamic Amenorrhea: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2017; 102(5): 1413-1439

Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB. A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update. 2006; 12(6): 685-718

Iliodromiti S, Kelsey TW, Anderson RA, Nelson SM. Can anti-Mullerian hormone predict the diagnosis of polycystic ovary syndrome? A systematic review and metaanalysis of extracted data. J Clin Endocrinol Metab. 2013; 98(8): 3332-3340

Zhang C-H, Ma K, Yuan B-C, Yuan Y, Chen Y-X. Bushen Huoxue herbal medicine for treating hyperprolactinemia in women: a Meta-analysis. Zhongguo Zhong Yao Za Zhi. 2019; 44(6): 1087-1093.

Amiri M, Tehrani FR, Bidhendi-Yarandi R, Behboudi-Gandevani S, Azizi F, Carmina E. Relationships Between Biochemical Markers of Hyperandrogenism and Metabolic Parameters in Women with Polycystic Ovary Syndrome: A Systematic Review and MetaAnalysis. Horm Metab Res. 2019; 51(1): 22-34

Dulohery K, Trottmann M, Bour S, Liedl B, Alba-Alejandre I, Reese S, et al. How do elevated levels of testosterone affect the function of the human fallopian tube and fertility? New insights. Mol Reprod Dev. 2020; 87(1): 30-44. doi: 10.1002/mrd.23291

Decanter C, Morschhauser F, Pigny P, Lefebvre C, Gallo C, Dewailly D. Anti-Müllerian hormone follow-up in young women treated by chemotherapy for lymphoma: preliminary results. Reprod Biomed Online. 2010; 20: B 280-285. doi: 10.1016/j. rbmo.2009.11.010

Lie Fong S, Laven JSE, Hakvoort-Cammel FGAJ, Schipper I, Visser JA, Themmen APN, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Müllerian hormone. Hum Reprod. 2009; 24: 982-990. doi: 10.1093/humrep/den487

Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril. 2012; 97: 134-140.e1. doi: 10.1016/j. fertnstert.2011.10.040

Anderson RA, Rosendahl M, Kelsey TW, Cameron DA. Pretreatment anti-Müllerian hormone predicts for loss of ovarian function after chemotherapy for early breast cancer. Eur J Cancer. 2013; 49: 3404-3411. doi: 10.1016/j.ejca.2013.07.014

Dillon KE, Sammel MD, Prewitt M, Ginsberg JP, Walker D, Mersereau JE, et al. Pretreatment antimüllerian hormone levels determine rate of posttherapy ovarian reserve recovery: acute changes in ovarian reserve during and after chemotherapy. Fertil Steril. 2013; 99: 477-483.e1. doi: 10.1016/j.fertnstert.2012.09.039

Rosendahl M, Andersen CY, la Cour Freiesleben N, Juul A, Løssl K, Andersen AN. Dynamics and mechanisms of chemotherapy-induced ovarian follicular depletion in women of fertile age. Fertil Steril. 2010; 94: 156-166. doi: 10.1016/j.fertnstert.2009.02.043

Lawrenz B, Mahajan N, Fatemi HM. The effects of cancer therapy on women’sfertility: what do we know now? Futur Oncol. 2016; 12: 1721-1729. doi: 10.2217/fon 2015–0004

Nelson SM, Yates RW, Fleming R. Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cyclesimplicationsfor individualization of therapy. Hum Reprod. 2007; 22: 2414-2421. doi: 10.1093/humrep/dem204

Broer SL, Dolleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJM. AMH and AFC as predictors of excessive in controlled ovarian hyperstimulation: a meta-analysis. Hum Reprod Update. 2011; 17: 46-54. doi: 10.1093/humupd/dmq034

Korevaar TIM, Derakhshan A, Taylor PN, Meima M, Chen L, Bliddal S, et al. Association of Thyroid Function Test Abnormalities and Thyroid Autoimmunity With Preterm Birth: A Systematic Review and Meta-analysis. JAMA. 2019; 322(7): 632-641

Busnelli A, Paffoni A, Fedele L, Somigliana E. The impact of thyroid autoimmunity on IVF/ICSI outcome: a systematic review and meta-analysis. Hum Reprod Update. 2016; 22(6): 775-790

Xiaoxia Chang et al. Effects of luteal estradiol pre-treatment on the outcome of IVF in poor ovarian responders. Gynecol Endocrinol. 2013; 29(3): 196-200

Clinical recommendation. Women infertility. 2021 (Клинические рекомендации. Женское бесплодие. 2021)

Machura P, Grymowicz M, Rudnicka E, Pięta W, Calik-Ksepka A, Skórska J, Smolarczyk R. Premature ovarian insufficiency - hormone replacement therapy and management of long-term consequences. Prz Menopauzalny. 2018; 17(3): 135-138. doi: 10.5114/pm.2018.78559

Męczekalski B, Maciejewska-Jeske M, Podfigurna A. Reproduction in premature ovarian insufficiency patients – from latest studies to therapeutic approach. Prz Menopauzalny. 2018; 17(3): 117-119. doi: 10.5114/pm.2018.78554

Atabiekov I, Hobeika E, Sheikh U, El Andaloussi A, Al-Hendy A. The Role of Gene Therapy in Premature Ovarian Insufficiency Management. Biomedicines. 2018; 6(4): 102. doi: 10.3390/biomedicines6040102

The use of estrogens in ART programs. Scientific and practical recommendations. RARH. 2015. Russian (Применение эстрогенов в программах ВРТ. Научно-практические рекомендации. РАРЧ. 2015)

Liao X, Li Z, Dong X, Zhang H. Comparison between oral and vaginal estrogen usage in inadequate endometrial patients for frozen-thawed blastocysts transfer. Int J Clin Exp Pathol. 2014; 7(10): 6992-6997

Jung H, Roh HK. The effects of E2 supplementation from the early proliferative phase to the late secretory phase of the endometrium in hMG-stimulated IVF-ET. J Assist Reprod Genet. 2000; 17(1): 28-33

Ghobara T, Gelbaya TA, Ayeleke RO. Cycle regimens for frozen-thawed embryo transfer. Cochrane Database Syst Rev. 2017

Vartanyan E, Tsaturova K, Devyatova E. Thin endometrium problem in IVF programs. Gynecol Endocrinol. 2020; 36(sup1): 24-27

Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. JAMA. 2005; 294(1): 91-96. doi: 10.1001/jama.294.1.91

Stanczyk FZ. Measurement of androgens in women. Semin Reprod Med. 2006; 24(2): 78-85. doi: 10.1055/s-2006-939566

Labrie F. Impact of circulating dehydroepiandrosterone on androgen formation in women. Menopause. 2011; 18(5): 471-473. doi: 10.1097/gme.0b013e3182146d7f

Buster JE. Transdermal menopausal hormone therapy: delivery through skin changes the rules. Expert Opin Pharmacother. 2010; 11(9): 1489-99. doi: 10.1517/14656561003774098

Blumenfeld Z. Front What Is the Best Regimen for Ovarian Stimulation of Poor Responders in ART/IVF? Endocrinol (Lausanne). 2020; 11: 192. doi: 10.3389/fendo.2020.00192

Kawamura K, Kawamura N, Hsueh AJ. Activation of dormant follicles: a new treatment for premature ovarian failure? Curr Opin Obstet Gynecol. 2016; 28(3): 217-222. doi: 10.1097/GCO.0000000000000268

Management of women with premature ovarian insufficiency. Guideline of the European Society of Human Reproduction and Embryology. December 2015


Статистика просмотров

Загрузка метрик ...

Ссылки

  • На текущий момент ссылки отсутствуют.